Identification of biomarkers in laryngeal cancer by weighted gene co-expression network analysis.
10.11817/j.issn.1672-7347.2023.220630
- Author:
Fengyu ZHANG
1
;
Li SHE
2
;
Donghai HUANG
3
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008. damaozfy@163.com.
2. Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008.
3. Department of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008. huang3301@126.com.
- Publication Type:Journal Article
- Keywords:
co-expression gene modules;
gene biomarker;
laryngeal cancer;
weighted gene co-expression network analysis
- MeSH:
Humans;
Laryngeal Neoplasms/genetics*;
Rosaniline Dyes;
Biomarkers;
Adipocytes;
Gene Regulatory Networks;
Gene Expression Profiling
- From:
Journal of Central South University(Medical Sciences)
2023;48(8):1136-1151
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Laryngeal cancer (LC) is a globally prevalent and highly lethal tumor. Despite extensive efforts, the underlying mechanisms of LC remain inadequately understood. This study aims to conduct an innovative bioinformatic analysis to identify hub genes that could potentially serve as biomarkers or therapeutic targets in LC.
METHODS:We acquired a dataset consisting of 117 LC patient samples, 16 746 LC gene RNA sequencing data points, and 9 clinical features from the Cancer Genome Atlas (TCGA) database in the United States. We employed weighted gene co-expression network analysis (WGCNA) to construct multiple co-expression gene modules. Subsequently, we assessed the correlations between these co-expression modules and clinical features to validate their associations. We also explored the interplay between modules to identify pivotal genes within disease pathways. Finally, we used the Kaplan-Meier plotter to validate the correlation between enriched genes and LC prognosis.
RESULTS:WGCNA analysis led to the creation of a total of 16 co-expression gene modules related to LC. Four of these modules (designated as the yellow, magenta, black, and brown modules) exhibited significant correlations with 3 clinical features: The age of initial pathological diagnosis, cancer status, and pathological N stage. Specifically, the yellow and magenta gene modules displayed negative correlations with the age of pathological diagnosis (r=-0.23, P<0.05; r=-0.33, P<0.05), while the black and brown gene modules demonstrated negative associations with cancer status (r=-0.39, P<0.05; r=-0.50, P<0.05). The brown gene module displayed a positive correlation with pathological N stage. Gene Ontology (GO) enrichment analysis identified 77 items, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis identified 30 related signaling pathways, including the calcium signaling pathway, cytokine-cytokine receptor interaction, neuro active ligand-receptor interaction, and regulation of lipolysis in adipocytes, etc. Consequently, central genes within these modules that were significantly linked to the overall survival rate of LC patients were identified. Central genes included CHRNB4, FOXL2, KCNG1, LOC440173, ADAMTS15, BMP2, FAP, and KIAA1644.
CONCLUSIONS:This study, utilizing WGCNA and subsequent validation, pinpointed 8 genes with potential as gene biomarkers for LC. These findings offer valuable references for the clinical diagnosis, prognosis, and treatment of LC.
